TY  - JOUR
AU  - Antal, Andrea
AU  - Ganho-Ávila, Ana
AU  - Assecondi, Sara
AU  - Barbour, Tracy
AU  - Bjekić, Jovana
AU  - Blumberger, Daniel M.
AU  - Bolognini, Nadia
AU  - Brunelin, Jerome
AU  - Chanes, Lorena
AU  - Dale, Matthew
AU  - Dubbioso, Raffaele
AU  - D'Urso, Giordano
AU  - Filipčić, Igor
AU  - Filipović, Saša
AU  - Hirnstein, Marco
AU  - Konings, Femke
AU  - Langguth, Berthold
AU  - Leocani, Letizia
AU  - Sorkhabi, Majid Memarian
AU  - Mulder, Marc
AU  - Nikander, Mika
AU  - Nowak, Rafal
AU  - Oliviero, Antonio
AU  - Onarheim, Balder
AU  - O'Shea, Jacinta
AU  - Pallanti, Stefano
AU  - Rachid, Fady
AU  - Rajão-Saraiva, Joana
AU  - Rossi, Simone
AU  - Sack, Alexander T.
AU  - Sauvaget, Anne
AU  - van der Scheer, Rik
AU  - Schellhorn, Klaus
AU  - Soria-Frisch, Aureli
AU  - Szekely, David
AU  - Tankisi, Hatice
AU  - Taylor, Paul CJ.
AU  - Tendolkar, Indira
AU  - Uusitalo, Susanne
AU  - Baeken, Chris
PY  - 2024
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/1479
AB  - A significant amount of European basic and clinical neuroscience research includes the use of transcranial magnetic stimulation (TMS) and low intensity transcranial electrical stimulation (tES), mainly transcranial direct current stimulation (tDCS). Two recent changes in the EU regulations, the introduction of the Medical Device Regulation (MDR) (2017/745) and the Annex XVI have caused significant problems and confusions in the brain stimulation field. The negative consequences of the MDR for non-invasive brain stimulation (NIBS) have been largely overlooked and until today, have not been consequently addressed by National Competent Authorities, local ethical committees, politicians and by the scientific communities. In addition, a rushed bureaucratic decision led to seemingly wrong classification of NIBS products without an intended medical purpose into the same risk group III as invasive stimulators. Overregulation is detrimental for any research and for future developments, therefore researchers, clinicians, industry, patient representatives and an ethicist were invited to contribute to this document with the aim of starting a constructive dialogue and enacting positive changes in the regulatory environment.
PB  - Elsevier
T2  - Clinical Neurophysiology
T1  - The consequences of the new European reclassification of non-invasive brain stimulation devices and the medical device regulations pose an existential threat to research and treatment: An invited opinion paper
DO  - 10.1016/j.clinph.2024.03.039
ER  - 

@article{
author = "Antal, Andrea and Ganho-Ávila, Ana and Assecondi, Sara and Barbour, Tracy and Bjekić, Jovana and Blumberger, Daniel M. and Bolognini, Nadia and Brunelin, Jerome and Chanes, Lorena and Dale, Matthew and Dubbioso, Raffaele and D'Urso, Giordano and Filipčić, Igor and Filipović, Saša and Hirnstein, Marco and Konings, Femke and Langguth, Berthold and Leocani, Letizia and Sorkhabi, Majid Memarian and Mulder, Marc and Nikander, Mika and Nowak, Rafal and Oliviero, Antonio and Onarheim, Balder and O'Shea, Jacinta and Pallanti, Stefano and Rachid, Fady and Rajão-Saraiva, Joana and Rossi, Simone and Sack, Alexander T. and Sauvaget, Anne and van der Scheer, Rik and Schellhorn, Klaus and Soria-Frisch, Aureli and Szekely, David and Tankisi, Hatice and Taylor, Paul CJ. and Tendolkar, Indira and Uusitalo, Susanne and Baeken, Chris",
year = "2024",
abstract = "A significant amount of European basic and clinical neuroscience research includes the use of transcranial magnetic stimulation (TMS) and low intensity transcranial electrical stimulation (tES), mainly transcranial direct current stimulation (tDCS). Two recent changes in the EU regulations, the introduction of the Medical Device Regulation (MDR) (2017/745) and the Annex XVI have caused significant problems and confusions in the brain stimulation field. The negative consequences of the MDR for non-invasive brain stimulation (NIBS) have been largely overlooked and until today, have not been consequently addressed by National Competent Authorities, local ethical committees, politicians and by the scientific communities. In addition, a rushed bureaucratic decision led to seemingly wrong classification of NIBS products without an intended medical purpose into the same risk group III as invasive stimulators. Overregulation is detrimental for any research and for future developments, therefore researchers, clinicians, industry, patient representatives and an ethicist were invited to contribute to this document with the aim of starting a constructive dialogue and enacting positive changes in the regulatory environment.",
publisher = "Elsevier",
journal = "Clinical Neurophysiology",
title = "The consequences of the new European reclassification of non-invasive brain stimulation devices and the medical device regulations pose an existential threat to research and treatment: An invited opinion paper",
doi = "10.1016/j.clinph.2024.03.039"
}

Antal, A., Ganho-Ávila, A., Assecondi, S., Barbour, T., Bjekić, J., Blumberger, D. M., Bolognini, N., Brunelin, J., Chanes, L., Dale, M., Dubbioso, R., D'Urso, G., Filipčić, I., Filipović, S., Hirnstein, M., Konings, F., Langguth, B., Leocani, L., Sorkhabi, M. M., Mulder, M., Nikander, M., Nowak, R., Oliviero, A., Onarheim, B., O'Shea, J., Pallanti, S., Rachid, F., Rajão-Saraiva, J., Rossi, S., Sack, A. T., Sauvaget, A., van der Scheer, R., Schellhorn, K., Soria-Frisch, A., Szekely, D., Tankisi, H., Taylor, P. CJ., Tendolkar, I., Uusitalo, S.,& Baeken, C.. (2024). The consequences of the new European reclassification of non-invasive brain stimulation devices and the medical device regulations pose an existential threat to research and treatment: An invited opinion paper. in Clinical Neurophysiology
Elsevier..
https://doi.org/10.1016/j.clinph.2024.03.039

Antal A, Ganho-Ávila A, Assecondi S, Barbour T, Bjekić J, Blumberger DM, Bolognini N, Brunelin J, Chanes L, Dale M, Dubbioso R, D'Urso G, Filipčić I, Filipović S, Hirnstein M, Konings F, Langguth B, Leocani L, Sorkhabi MM, Mulder M, Nikander M, Nowak R, Oliviero A, Onarheim B, O'Shea J, Pallanti S, Rachid F, Rajão-Saraiva J, Rossi S, Sack AT, Sauvaget A, van der Scheer R, Schellhorn K, Soria-Frisch A, Szekely D, Tankisi H, Taylor PC, Tendolkar I, Uusitalo S, Baeken C. The consequences of the new European reclassification of non-invasive brain stimulation devices and the medical device regulations pose an existential threat to research and treatment: An invited opinion paper. in Clinical Neurophysiology. 2024;.
doi:10.1016/j.clinph.2024.03.039 .

Antal, Andrea, Ganho-Ávila, Ana, Assecondi, Sara, Barbour, Tracy, Bjekić, Jovana, Blumberger, Daniel M., Bolognini, Nadia, Brunelin, Jerome, Chanes, Lorena, Dale, Matthew, Dubbioso, Raffaele, D'Urso, Giordano, Filipčić, Igor, Filipović, Saša, Hirnstein, Marco, Konings, Femke, Langguth, Berthold, Leocani, Letizia, Sorkhabi, Majid Memarian, Mulder, Marc, Nikander, Mika, Nowak, Rafal, Oliviero, Antonio, Onarheim, Balder, O'Shea, Jacinta, Pallanti, Stefano, Rachid, Fady, Rajão-Saraiva, Joana, Rossi, Simone, Sack, Alexander T., Sauvaget, Anne, van der Scheer, Rik, Schellhorn, Klaus, Soria-Frisch, Aureli, Szekely, David, Tankisi, Hatice, Taylor, Paul CJ., Tendolkar, Indira, Uusitalo, Susanne, Baeken, Chris, "The consequences of the new European reclassification of non-invasive brain stimulation devices and the medical device regulations pose an existential threat to research and treatment: An invited opinion paper" in Clinical Neurophysiology (2024),
https://doi.org/10.1016/j.clinph.2024.03.039 . .

TY  - JOUR
AU  - Lefaucheur, Jean-Pascal
AU  - Aleman, Andre
AU  - Baeken, Chris
AU  - Benninger, David H.
AU  - Brunelin, Jerome
AU  - Di Lazzaro, Vincenzo
AU  - Filipović, Saša
AU  - Grefkes, Christian
AU  - Hasan, Alkomiet
AU  - Hummel, Friedhelm C.
AU  - Jaaskelainen, Satu K.
AU  - Langguth, Berthold
AU  - Leocani, Letizia
AU  - Londero, Alain
AU  - Nardone, Raffaele
AU  - Nguyen, Jean-Paul
AU  - Nyffeler, Thomas
AU  - Oliveira-Maia, Albino J.
AU  - Oliviero, Antonio
AU  - Padberg, Frank
AU  - Palm, Ulrich
AU  - Paulus, Walter
AU  - Poulet, Emmanuel
AU  - Quartarone, Angelo
AU  - Rachid, Fady
AU  - Rektorova, Irena
AU  - Rossi, Simone
AU  - Sahlsten, Hanna
AU  - Schecklmann, Martin
AU  - Szekely, David
AU  - Ziemann, Ulf
PY  - 2020
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/1032
AB  - A group of European experts reappraised the guidelines on the therapeutic efficacy of repetitive transcranial magnetic stimulation (rTMS) previously published in 2014 [Lefaucheur et al., Clin Neurophysiol 2014;125:2150-206]. These updated recommendations take into account all rTMS publications, including data prior to 2014, as well as currently reviewed literature until the end of 2018. Level A evidence (definite efficacy) was reached for: high-frequency (HF) rTMS of the primary motor cortex (M1) contralateral to the painful side for neuropathic pain; HF-rTMS of the left dorsolateral prefrontal cortex (DLPFC) using a figure-of-8 or a Hl-coil for depression; low-frequency (LF) rTMS of contralesional M1 for hand motor recovery in the post-acute stage of stroke. Level B evidence (probable efficacy) was reached for: HF-rTMS of the left M1 or DLPFC for improving quality of life or pain, respectively, in fibromyalgia; HF-rTMS of bilateral M1 regions or the left DLPFC for improving motor impairment or depression, respectively, in Parkinson's disease; HF-rTMS of ipsilesional M1 for promoting motor recovery at the post-acute stage of stroke; intermittent theta burst stimulation targeted to the leg motor cortex for lower limb spasticity in multiple sclerosis; HF-rTMS of the right DLPFC in posttraumatic stress disorder; LF-rTMS of the right inferior frontal gyrus in chronic post-stroke non-fluent aphasia; LF-rTMS of the right DLPFC in depression; and bihemispheric stimulation of the DLPFC combining right-sided LF-rTMS (or continuous theta burst stimulation) and left-sided HF-rTMS (or intermittent theta burst stimulation) in depression. Level A/B evidence is not reached concerning efficacy of rTMS in any other condition. The current recommendations are based on the differences reached in therapeutic efficacy of real vs. sham rTMS protocols, replicated in a sufficient number of independent studies. This does not mean that the benefit produced by rTMS inevitably reaches a level of clinical relevance.
PB  - Elsevier Ireland Ltd, Clare
T2  - Clinical Neurophysiology
T1  - Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018)
EP  - 528
IS  - 2
SP  - 474
VL  - 131
DO  - 10.1016/j.clinph.2019.11.002
ER  - 

@article{
author = "Lefaucheur, Jean-Pascal and Aleman, Andre and Baeken, Chris and Benninger, David H. and Brunelin, Jerome and Di Lazzaro, Vincenzo and Filipović, Saša and Grefkes, Christian and Hasan, Alkomiet and Hummel, Friedhelm C. and Jaaskelainen, Satu K. and Langguth, Berthold and Leocani, Letizia and Londero, Alain and Nardone, Raffaele and Nguyen, Jean-Paul and Nyffeler, Thomas and Oliveira-Maia, Albino J. and Oliviero, Antonio and Padberg, Frank and Palm, Ulrich and Paulus, Walter and Poulet, Emmanuel and Quartarone, Angelo and Rachid, Fady and Rektorova, Irena and Rossi, Simone and Sahlsten, Hanna and Schecklmann, Martin and Szekely, David and Ziemann, Ulf",
year = "2020",
abstract = "A group of European experts reappraised the guidelines on the therapeutic efficacy of repetitive transcranial magnetic stimulation (rTMS) previously published in 2014 [Lefaucheur et al., Clin Neurophysiol 2014;125:2150-206]. These updated recommendations take into account all rTMS publications, including data prior to 2014, as well as currently reviewed literature until the end of 2018. Level A evidence (definite efficacy) was reached for: high-frequency (HF) rTMS of the primary motor cortex (M1) contralateral to the painful side for neuropathic pain; HF-rTMS of the left dorsolateral prefrontal cortex (DLPFC) using a figure-of-8 or a Hl-coil for depression; low-frequency (LF) rTMS of contralesional M1 for hand motor recovery in the post-acute stage of stroke. Level B evidence (probable efficacy) was reached for: HF-rTMS of the left M1 or DLPFC for improving quality of life or pain, respectively, in fibromyalgia; HF-rTMS of bilateral M1 regions or the left DLPFC for improving motor impairment or depression, respectively, in Parkinson's disease; HF-rTMS of ipsilesional M1 for promoting motor recovery at the post-acute stage of stroke; intermittent theta burst stimulation targeted to the leg motor cortex for lower limb spasticity in multiple sclerosis; HF-rTMS of the right DLPFC in posttraumatic stress disorder; LF-rTMS of the right inferior frontal gyrus in chronic post-stroke non-fluent aphasia; LF-rTMS of the right DLPFC in depression; and bihemispheric stimulation of the DLPFC combining right-sided LF-rTMS (or continuous theta burst stimulation) and left-sided HF-rTMS (or intermittent theta burst stimulation) in depression. Level A/B evidence is not reached concerning efficacy of rTMS in any other condition. The current recommendations are based on the differences reached in therapeutic efficacy of real vs. sham rTMS protocols, replicated in a sufficient number of independent studies. This does not mean that the benefit produced by rTMS inevitably reaches a level of clinical relevance.",
publisher = "Elsevier Ireland Ltd, Clare",
journal = "Clinical Neurophysiology",
title = "Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018)",
pages = "528-474",
number = "2",
volume = "131",
doi = "10.1016/j.clinph.2019.11.002"
}

Lefaucheur, J., Aleman, A., Baeken, C., Benninger, D. H., Brunelin, J., Di Lazzaro, V., Filipović, S., Grefkes, C., Hasan, A., Hummel, F. C., Jaaskelainen, S. K., Langguth, B., Leocani, L., Londero, A., Nardone, R., Nguyen, J., Nyffeler, T., Oliveira-Maia, A. J., Oliviero, A., Padberg, F., Palm, U., Paulus, W., Poulet, E., Quartarone, A., Rachid, F., Rektorova, I., Rossi, S., Sahlsten, H., Schecklmann, M., Szekely, D.,& Ziemann, U.. (2020). Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018). in Clinical Neurophysiology
Elsevier Ireland Ltd, Clare., 131(2), 474-528.
https://doi.org/10.1016/j.clinph.2019.11.002

Lefaucheur J, Aleman A, Baeken C, Benninger DH, Brunelin J, Di Lazzaro V, Filipović S, Grefkes C, Hasan A, Hummel FC, Jaaskelainen SK, Langguth B, Leocani L, Londero A, Nardone R, Nguyen J, Nyffeler T, Oliveira-Maia AJ, Oliviero A, Padberg F, Palm U, Paulus W, Poulet E, Quartarone A, Rachid F, Rektorova I, Rossi S, Sahlsten H, Schecklmann M, Szekely D, Ziemann U. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018). in Clinical Neurophysiology. 2020;131(2):474-528.
doi:10.1016/j.clinph.2019.11.002 .

Lefaucheur, Jean-Pascal, Aleman, Andre, Baeken, Chris, Benninger, David H., Brunelin, Jerome, Di Lazzaro, Vincenzo, Filipović, Saša, Grefkes, Christian, Hasan, Alkomiet, Hummel, Friedhelm C., Jaaskelainen, Satu K., Langguth, Berthold, Leocani, Letizia, Londero, Alain, Nardone, Raffaele, Nguyen, Jean-Paul, Nyffeler, Thomas, Oliveira-Maia, Albino J., Oliviero, Antonio, Padberg, Frank, Palm, Ulrich, Paulus, Walter, Poulet, Emmanuel, Quartarone, Angelo, Rachid, Fady, Rektorova, Irena, Rossi, Simone, Sahlsten, Hanna, Schecklmann, Martin, Szekely, David, Ziemann, Ulf, "Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018)" in Clinical Neurophysiology, 131, no. 2 (2020):474-528,
https://doi.org/10.1016/j.clinph.2019.11.002 . .

TY  - JOUR
AU  - Lefaucheur, Jean-Pascal
AU  - Aleman, Andre
AU  - Baeken, Chris
AU  - Benninger, David H.
AU  - Brunelin, Jerome
AU  - Di Lazzaro, Vincenzo
AU  - Filipović, Saša
AU  - Grefkes, Christian
AU  - Hasan, Alkomiet
AU  - Hummel, Friedhelm C.
AU  - Jaaskelainen, Satu K.
AU  - Langguth, Berthold
AU  - Leocani, Letizia
AU  - Londero, Alain
AU  - Nardone, Raffaele
AU  - Nguyen, Jean-Paul
AU  - Nyffeler, Thomas
AU  - Oliveira-Maia, Albino J.
AU  - Oliviero, Antonio
AU  - Padberg, Frank
AU  - Palm, Ulrich
AU  - Paulus, Walter
AU  - Poulet, Emmanuel
AU  - Quartarone, Angelo
AU  - Rachid, Fady
AU  - Rektorova, Irena
AU  - Rossi, Simone
AU  - Sahlsten, Hanna
AU  - Schecklmann, Martin
AU  - Szekely, David
AU  - Ziemann, Ulf
PY  - 2020
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/1054
PB  - Elsevier Ireland Ltd, Clare
T2  - Clinical Neurophysiology
T1  - Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018) (vol 131, pg 474, 2020)
EP  - 1169
IS  - 5
SP  - 1168
VL  - 131
DO  - 10.1016/j.clinph.2020.02.003
ER  - 

@article{
author = "Lefaucheur, Jean-Pascal and Aleman, Andre and Baeken, Chris and Benninger, David H. and Brunelin, Jerome and Di Lazzaro, Vincenzo and Filipović, Saša and Grefkes, Christian and Hasan, Alkomiet and Hummel, Friedhelm C. and Jaaskelainen, Satu K. and Langguth, Berthold and Leocani, Letizia and Londero, Alain and Nardone, Raffaele and Nguyen, Jean-Paul and Nyffeler, Thomas and Oliveira-Maia, Albino J. and Oliviero, Antonio and Padberg, Frank and Palm, Ulrich and Paulus, Walter and Poulet, Emmanuel and Quartarone, Angelo and Rachid, Fady and Rektorova, Irena and Rossi, Simone and Sahlsten, Hanna and Schecklmann, Martin and Szekely, David and Ziemann, Ulf",
year = "2020",
publisher = "Elsevier Ireland Ltd, Clare",
journal = "Clinical Neurophysiology",
title = "Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018) (vol 131, pg 474, 2020)",
pages = "1169-1168",
number = "5",
volume = "131",
doi = "10.1016/j.clinph.2020.02.003"
}

Lefaucheur, J., Aleman, A., Baeken, C., Benninger, D. H., Brunelin, J., Di Lazzaro, V., Filipović, S., Grefkes, C., Hasan, A., Hummel, F. C., Jaaskelainen, S. K., Langguth, B., Leocani, L., Londero, A., Nardone, R., Nguyen, J., Nyffeler, T., Oliveira-Maia, A. J., Oliviero, A., Padberg, F., Palm, U., Paulus, W., Poulet, E., Quartarone, A., Rachid, F., Rektorova, I., Rossi, S., Sahlsten, H., Schecklmann, M., Szekely, D.,& Ziemann, U.. (2020). Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018) (vol 131, pg 474, 2020). in Clinical Neurophysiology
Elsevier Ireland Ltd, Clare., 131(5), 1168-1169.
https://doi.org/10.1016/j.clinph.2020.02.003

Lefaucheur J, Aleman A, Baeken C, Benninger DH, Brunelin J, Di Lazzaro V, Filipović S, Grefkes C, Hasan A, Hummel FC, Jaaskelainen SK, Langguth B, Leocani L, Londero A, Nardone R, Nguyen J, Nyffeler T, Oliveira-Maia AJ, Oliviero A, Padberg F, Palm U, Paulus W, Poulet E, Quartarone A, Rachid F, Rektorova I, Rossi S, Sahlsten H, Schecklmann M, Szekely D, Ziemann U. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018) (vol 131, pg 474, 2020). in Clinical Neurophysiology. 2020;131(5):1168-1169.
doi:10.1016/j.clinph.2020.02.003 .

Lefaucheur, Jean-Pascal, Aleman, Andre, Baeken, Chris, Benninger, David H., Brunelin, Jerome, Di Lazzaro, Vincenzo, Filipović, Saša, Grefkes, Christian, Hasan, Alkomiet, Hummel, Friedhelm C., Jaaskelainen, Satu K., Langguth, Berthold, Leocani, Letizia, Londero, Alain, Nardone, Raffaele, Nguyen, Jean-Paul, Nyffeler, Thomas, Oliveira-Maia, Albino J., Oliviero, Antonio, Padberg, Frank, Palm, Ulrich, Paulus, Walter, Poulet, Emmanuel, Quartarone, Angelo, Rachid, Fady, Rektorova, Irena, Rossi, Simone, Sahlsten, Hanna, Schecklmann, Martin, Szekely, David, Ziemann, Ulf, "Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018) (vol 131, pg 474, 2020)" in Clinical Neurophysiology, 131, no. 5 (2020):1168-1169,
https://doi.org/10.1016/j.clinph.2020.02.003 . .

TY  - JOUR
AU  - Lefaucheur, Jean-Pascal
AU  - Andre-Obadia, Nathalie
AU  - Antal, Andrea
AU  - Ayache, Samar S.
AU  - Baeken, Chris
AU  - Benninger, David H.
AU  - Cantello, Roberto M.
AU  - Cincotta, Massimo
AU  - de Carvalho, Mamede
AU  - De Ridder, Dirk
AU  - Devanne, Herve
AU  - Di Lazzaro, Vincenzo
AU  - Filipović, Saša
AU  - Hummel, Friedhelm C.
AU  - Jaaskelainen, Satu K.
AU  - Kimiskidis, Vasilios K.
AU  - Koch, Giacomo
AU  - Langguth, Berthold
AU  - Nyffeler, Thomas
AU  - Oliviero, Antonio
AU  - Padberg, Frank
AU  - Poulet, Emmanuel
AU  - Rossi, Simone
AU  - Rossini, Paolo Maria
AU  - Rothwell, John C.
AU  - Schonfeldt-Lecuona, Carlos
AU  - Siebner, Hartwig R.
AU  - Slotema, Christina W.
AU  - Stagg, Charlotte J.
AU  - Valls-Sole, Josep
AU  - Ziemann, Ulf
AU  - Paulus, Walter
AU  - Garcia-Larrea, Luis
PY  - 2014
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/555
AB  - A group of European experts was commissioned to establish guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS) from evidence published up until March 2014, regarding pain, movement disorders, stroke, amyotrophic lateral sclerosis, multiple sclerosis, epilepsy, consciousness disorders, tinnitus, depression, anxiety disorders, obsessive-compulsive disorder, schizophrenia, craving/addiction, and conversion. Despite unavoidable inhomogeneities, there is a sufficient body of evidence to accept with level A (definite efficacy) the analgesic effect of high-frequency (HF) rTMS of the primary motor cortex (M1) contralateral to the pain and the antidepressant effect of HF-rTMS of the left dorsolateral prefrontal cortex (DLPFC). A Level B recommendation (probable efficacy) is proposed for the antidepressant effect of low-frequency (LF) rTMS of the right DLPFC, HF-rTMS of the left DLPFC for the negative symptoms of schizophrenia, and LF-rTMS of contralesional M1 in chronic motor stroke. The effects of rTMS in a number of indications reach level C (possible efficacy), including LF-rTMS of the left temporoparietal cortex in tinnitus and auditory hallucinations. It remains to determine how to optimize rTMS protocols and techniques to give them relevance in routine clinical practice. In addition, professionals carrying out rTMS protocols should undergo rigorous training to ensure the quality of the technical realization, guarantee the proper care of patients, and maximize the chances of success. Under these conditions, the therapeutic use of rTMS should be able to develop in the coming years.
PB  - Elsevier Ireland Ltd, Clare
T2  - Clinical Neurophysiology
T1  - Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS)
EP  - 2206
IS  - 11
SP  - 2150
VL  - 125
DO  - 10.1016/j.clinph.2014.05.021
ER  - 

@article{
author = "Lefaucheur, Jean-Pascal and Andre-Obadia, Nathalie and Antal, Andrea and Ayache, Samar S. and Baeken, Chris and Benninger, David H. and Cantello, Roberto M. and Cincotta, Massimo and de Carvalho, Mamede and De Ridder, Dirk and Devanne, Herve and Di Lazzaro, Vincenzo and Filipović, Saša and Hummel, Friedhelm C. and Jaaskelainen, Satu K. and Kimiskidis, Vasilios K. and Koch, Giacomo and Langguth, Berthold and Nyffeler, Thomas and Oliviero, Antonio and Padberg, Frank and Poulet, Emmanuel and Rossi, Simone and Rossini, Paolo Maria and Rothwell, John C. and Schonfeldt-Lecuona, Carlos and Siebner, Hartwig R. and Slotema, Christina W. and Stagg, Charlotte J. and Valls-Sole, Josep and Ziemann, Ulf and Paulus, Walter and Garcia-Larrea, Luis",
year = "2014",
abstract = "A group of European experts was commissioned to establish guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS) from evidence published up until March 2014, regarding pain, movement disorders, stroke, amyotrophic lateral sclerosis, multiple sclerosis, epilepsy, consciousness disorders, tinnitus, depression, anxiety disorders, obsessive-compulsive disorder, schizophrenia, craving/addiction, and conversion. Despite unavoidable inhomogeneities, there is a sufficient body of evidence to accept with level A (definite efficacy) the analgesic effect of high-frequency (HF) rTMS of the primary motor cortex (M1) contralateral to the pain and the antidepressant effect of HF-rTMS of the left dorsolateral prefrontal cortex (DLPFC). A Level B recommendation (probable efficacy) is proposed for the antidepressant effect of low-frequency (LF) rTMS of the right DLPFC, HF-rTMS of the left DLPFC for the negative symptoms of schizophrenia, and LF-rTMS of contralesional M1 in chronic motor stroke. The effects of rTMS in a number of indications reach level C (possible efficacy), including LF-rTMS of the left temporoparietal cortex in tinnitus and auditory hallucinations. It remains to determine how to optimize rTMS protocols and techniques to give them relevance in routine clinical practice. In addition, professionals carrying out rTMS protocols should undergo rigorous training to ensure the quality of the technical realization, guarantee the proper care of patients, and maximize the chances of success. Under these conditions, the therapeutic use of rTMS should be able to develop in the coming years.",
publisher = "Elsevier Ireland Ltd, Clare",
journal = "Clinical Neurophysiology",
title = "Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS)",
pages = "2206-2150",
number = "11",
volume = "125",
doi = "10.1016/j.clinph.2014.05.021"
}

Lefaucheur, J., Andre-Obadia, N., Antal, A., Ayache, S. S., Baeken, C., Benninger, D. H., Cantello, R. M., Cincotta, M., de Carvalho, M., De Ridder, D., Devanne, H., Di Lazzaro, V., Filipović, S., Hummel, F. C., Jaaskelainen, S. K., Kimiskidis, V. K., Koch, G., Langguth, B., Nyffeler, T., Oliviero, A., Padberg, F., Poulet, E., Rossi, S., Rossini, P. M., Rothwell, J. C., Schonfeldt-Lecuona, C., Siebner, H. R., Slotema, C. W., Stagg, C. J., Valls-Sole, J., Ziemann, U., Paulus, W.,& Garcia-Larrea, L.. (2014). Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). in Clinical Neurophysiology
Elsevier Ireland Ltd, Clare., 125(11), 2150-2206.
https://doi.org/10.1016/j.clinph.2014.05.021

Lefaucheur J, Andre-Obadia N, Antal A, Ayache SS, Baeken C, Benninger DH, Cantello RM, Cincotta M, de Carvalho M, De Ridder D, Devanne H, Di Lazzaro V, Filipović S, Hummel FC, Jaaskelainen SK, Kimiskidis VK, Koch G, Langguth B, Nyffeler T, Oliviero A, Padberg F, Poulet E, Rossi S, Rossini PM, Rothwell JC, Schonfeldt-Lecuona C, Siebner HR, Slotema CW, Stagg CJ, Valls-Sole J, Ziemann U, Paulus W, Garcia-Larrea L. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). in Clinical Neurophysiology. 2014;125(11):2150-2206.
doi:10.1016/j.clinph.2014.05.021 .

Lefaucheur, Jean-Pascal, Andre-Obadia, Nathalie, Antal, Andrea, Ayache, Samar S., Baeken, Chris, Benninger, David H., Cantello, Roberto M., Cincotta, Massimo, de Carvalho, Mamede, De Ridder, Dirk, Devanne, Herve, Di Lazzaro, Vincenzo, Filipović, Saša, Hummel, Friedhelm C., Jaaskelainen, Satu K., Kimiskidis, Vasilios K., Koch, Giacomo, Langguth, Berthold, Nyffeler, Thomas, Oliviero, Antonio, Padberg, Frank, Poulet, Emmanuel, Rossi, Simone, Rossini, Paolo Maria, Rothwell, John C., Schonfeldt-Lecuona, Carlos, Siebner, Hartwig R., Slotema, Christina W., Stagg, Charlotte J., Valls-Sole, Josep, Ziemann, Ulf, Paulus, Walter, Garcia-Larrea, Luis, "Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS)" in Clinical Neurophysiology, 125, no. 11 (2014):2150-2206,
https://doi.org/10.1016/j.clinph.2014.05.021 . .